A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Poland- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Ul. Julianowska 54b, 91-473 Lodz, Poland
Clinicly Sp. z o.o. in Lodz, Poland specialises in clinical trials of conditions such as Peripheral arterial occlusive disease, and other specialisations. This site conducts important research.
Clinical trials currently enrolling participants at this site.
PolandEfficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization
PolandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.